Patents by Inventor Matthias W. Rath

Matthias W. Rath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12029726
    Abstract: A micronutrient composition is highly effective in treating joint related inflammation and reducing ECM damaging enzymes in joints. The micronutrient composition comprises of Vitamin C, Vitamin E (D-alpha tocopherol), Vitamin B6, Vitamin D3, Folic acid, L-proline, L-lysine, Copper, Betaine HCl, Chondroitin sulfate, N-acetyl-glucosamine, Pycnogenol, SAMe, Cat's claw, Boswellia serrata, Stinging nettle and Glutamine. The micronutrient composition was most effective in supporting critical cellular mechanisms important for healthy joints-increased production and deposition of important ECM components by synovial cells and chondrocytes under pro-inflammatory conditions (presence of LPS). The micronutrient composition also decreased pro-inflammatory IL-6 and decreased secretion of MMP13, the ECM damaging enzyme in joints.
    Type: Grant
    Filed: July 6, 2023
    Date of Patent: July 9, 2024
    Inventor: Matthias W Rath
  • Patent number: 11986507
    Abstract: A micronutrient composition shown as Mix 1 comprises Rosemary extract at 1 mg-6,000 mg, Fenugreek extract 1 mg-50,000 mg and Fenugreek seed powder at 2 mg-8,000 mg, Cassia nomane seed extract powder 1 mg to 1,000 mg and dry extract 1 mg-300 mg, 3?3-di indolylmethylene 1 mg-800 mg, Zinc 0.1 mg-1,000 mg, Phosphatidylserine 1 mg-1,500 mg, Vitamin D 20 IU-10,000 IU, Vitamin C 10 mg-50,000 mg, Niacin 1 mg-3,000 mg, Theanine 0.1 mg-10,000 mg, Aspartic acid 10 mg-10,000 mg, Arginine 10 mg-50,000 mg and Dehydroepiandrosterone (DHEA) 1 mg-500 mg and Mix A comprising of all the ingredients of Mix 1 but does not contain DHEA and both are used improve men's health.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: May 21, 2024
    Inventor: Matthias W Rath
  • Patent number: 11717013
    Abstract: A micronutrient composition is highly effective in relaxing smooth muscle cells in bronchial cell and uterine cell during a specific disease. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9(folate) and vitamin B12, magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of smooth muscle cells important in providing much needed relief to breathe during airway constriction in asthma and uterine smooth muscle cell during premenstrual pain.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: August 8, 2023
    Inventor: Matthias W Rath
  • Patent number: 11679096
    Abstract: The Basic Mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1 mg-3,000 mg, Vitamin B5 1 mg-20,000 mg, Vitamin B6 1 mg-1,000 mg, Folic acid 1 mcg-3,000 mcg, Iodine (Kelp) 1 mcg-2,000 mcg, Selenium 1 mcg-2,000 mcg, Choline 1 mg-5,000 mg, Inositol 1 mg-5000 mg, Phosphatidyl serine 1 mg-1,500 mg, Soy extract containing Daidzein 1 mg-1,500 mg, Glycitein 0.1 mg-1,000 mg, and Genistein 1 mg-2,500 mg, Red clover 1 mg-1,500 mg, Rosemary extract 1 mg-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1 mg-2,000 mg. Mix 1 is effective in repressing the transcription of ApoE gene in fibroblast cells. The formulations counters specific pathology markers, alleviates markers associated with increased risk of degenerative problems (i.e. Alzheimer's disease).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: June 20, 2023
    Inventor: Matthias W Rath
  • Patent number: 11666643
    Abstract: A micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12, magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: June 6, 2023
    Inventor: Matthias W Rath
  • Patent number: 11654131
    Abstract: A basic mix or Mix 1 or Mix 2 is highly effective in treating estrogen related complications in females. The estrogen related diseases such as cancer are also treated if they are Apo E based manifestations. The basic mix or Mix 1 or Mix 2 comprises of a combination of a Vitamin C (Ca ascorbate) 10 mg-100,000 mg, Vitamin E (D-alpha-tocopherol) 1-3,000 mg, Vitamin B5 1-20,000 mg, Vitamin B6 1-1,000 mg, Folic acid 1-3,000 mcg, Iodine (Kelp) 1-2,000 mcg, Selenium 1-2,000 mcg, Choline 1-5,000 mg, Inositol 1-5000 mg, Phosphatidyl serine 1-1,500 mg, Daidzein 1-1,500 mg, Glycitein 0.1-1,000 mg, Genistein 1-2,500 mg, Red clover 1-1,500 mg, Rosemary extract 1-6,000 mg and Chaste tree berry (Vitex agnus-castus) 1-2,000 mg. The treatment by administering Mix 1 decreases estrogen dependent breast cancer cells proliferation and decrease in expression of cancer promoting cellular markers in cancer cells (iNOS, ApoE).
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: May 23, 2023
    Inventor: Matthias W Rath
  • Patent number: 11571468
    Abstract: A micronutrient composition is highly effective in controlling high blood pressure while given to mammal for treating with or without prescribed pharmaceutical drug. The micronutrient composition comprises of vitamin C, vitamin D3, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9 and vitamin B12 and calcium and magnesium, clove extract, grape extract, celery extract and L-arginine. This micronutrient composition supports critical cellular mechanisms involved in the relaxation of vascular smooth muscle cells important in maintaining healthy blood pressure. The combined effects of the micronutrients contained in the micronutrient composition include increased production of NO “relaxing factor” and decreased activity of Angiotensin converting enzyme 1 (ACE1). ACE1 inhibitory effect of this natural formula was more pronounced than obtained with the pharmaceutical ACE1 inhibitor—Lisinopril—the commonly prescribed high blood pressure medication.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: February 7, 2023
    Inventor: Matthias W Rath
  • Patent number: 11452710
    Abstract: The micronutrient and plant extract composition comprises of a vitamin C, vitamin A (?-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract and in combination it is used for treating, and reversing bone demineralization. The micronutrient and plant extract composition when administered to mammal with or without bone disease strengthens and helps in bone mineralization process. The composition can be used as a preventive dose for bone demineralization in human.
    Type: Grant
    Filed: February 17, 2022
    Date of Patent: September 27, 2022
    Inventor: Matthias W Rath
  • Patent number: 11419847
    Abstract: Pharmaceutical micronutrient composition including mixture D in this study helps to mitigate, inhibit, prevent and stop diseases caused by viral infections. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Additional micronutrients were tested with Mixture D and seemed to have beneficial effects.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: August 23, 2022
    Inventor: Matthias W Rath
  • Patent number: 11351148
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: June 7, 2022
    Inventor: Matthias W Rath
  • Patent number: 11337959
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix B shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: December 26, 2021
    Date of Patent: May 24, 2022
    Inventor: Matthias W Rath
  • Patent number: 11304921
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Combination of L-theanine, Rhodiola rosea, Acetyl L-Carnitine (ALCAR), Bacopa monnieri, Mucuna pruriens, NAD+, Rose hips extract (trans-tiliroside), American Ginseng, Pyrroloquinoline quinone, Gotu Kola in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Patent number: 11304922
    Abstract: A pharmaceutical composition of micronutrients were tried to improve cognitive brain function, brain health and nervous system functions. Combination consisting of Avena sativa (green oat straw extract), Coenzyme Q10, NAD+, American Ginseng, and Pyrroloquinoline quinone in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: April 19, 2022
    Inventor: Matthias W Rath
  • Patent number: 11246855
    Abstract: A threefold decrease in ?-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: February 15, 2022
    Inventor: Matthias W Rath
  • Patent number: 11234952
    Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12, 10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: February 1, 2022
    Inventor: Matthias W Rath
  • Patent number: 11135196
    Abstract: The study shows that ascorbic acid and its combination with some natural compounds could be included in developing preventive and therapeutic approaches toward the current pandemic. Some natural compounds were effective in lowering ACE2 cellular expression, with the highest inhibitory effects observed for baicalin (75%) and theaflavin (50%). Significantly, combinations of these and other test compounds with ascorbic acid further decreased ACE2 expression. The highest impact of ascorbate on ACE2 expression was noted when combined with theaflavin (decrease from 50% to 87%), zinc aspartate (decrease from 22% to 62%), and with 10-undecenoic acid (from 18% to 53%). Our study provides valuable experimental confirmation of the efficacy of micronutrients in controlling ACE2 expression—the coronavirus cellular “entry” point. It further validates the importance of nutrient interactions in various aspects of cellular metabolism and in considering potential therapeutic applications of nutrient-based approaches.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: October 5, 2021
    Inventor: Matthias W Rath
  • Patent number: 10968441
    Abstract: The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQ ID NO: wherein the matrix metalloproteinase oligopeptide is at least one of SEQ ID NO: 7, 11, 12, 18 and 19 and combination thereof. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. The instance method is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 6, 2021
    Inventor: Matthias W. Rath
  • Patent number: 10736872
    Abstract: A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: August 11, 2020
    Inventor: Matthias W Rath
  • Patent number: 10716767
    Abstract: The nutrient mixture made up of vitamin, carotenoid, micronutrient, essential trace element, and plant extract was much more effective in proactively protecting the corneal cells (human) and retinal pigment endothelial cells (rat) against damaging effects of H2O2 and glycosylated proteins (AGE-BSA) compared to its individual components. A mixture is made up of vitamin A, vitamin C, vitamin E, Lycopene, lutein, marigold flower extract, a saffron extract, pine bark extract, grape seed extract, bilberry extract, lipoic acid, L-Arginine and zinc.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 21, 2020
    Inventors: Aleksandra Niedzwiecki, Matthias W Rath, Anna Goc, Waldemar Sumera
  • Patent number: 10610474
    Abstract: A mixture, comprising at least three, two or four different chemical compounds, selected from the group eicosapentaenoic acid, usnic acid, norspermidine, clove oil and 10-undecynoic acid is used in dental health compositions. The mixture is used for dental hygiene for controlling Streptococcus mutans and Candida albicans.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: April 7, 2020
    Inventor: Matthias W Rath